NAP1L4 and cancer: Finally, 15 candidate biomarkers (autoantibodies to RUNX1T1, RAD23A, CAST, PRKCZ, SF3B3, SARS, DUSP6, PAIP1, SH2B1, NAP1L4, CRLF3, LARP6, NOL7, MAGEA12, and CCDC6) were screened out based on the cancer literature and the database.